As of November 10, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Editas Medicine, Inc. The largest reported stake is Commodore Capital LP's, at 9.9%. 7 filings are on record since March 26, 2026 (Schedule 13G, June 2, 2026).
Sell to companies like Editas Medicine, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 11,732,765 · Shared voting: 0 · Sole dispositive: 11,937,882 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 8,889,000 · Sole dispositive: 0 · Shared dispositive: 8,889,000 · SCHEDULE 13G, 2026-08-14
- · Holder: BlackRock, Inc. · Percent: 4.97% · SCHEDULE 13G/A
- · Reporting person: TCG Crossover GP III, LLC · Sole voting: 0 · Shared voting: 15,798,999 · Sole dispositive: 0 · Shared dispositive: 15,798,999 · SCHEDULE 13G, 2026-06-03
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 8,889,000 · Sole dispositive: 0 · Shared dispositive: 8,889,000 · SCHEDULE 13G, 2026-06-03
Editas Medicine, Inc. has 7 Schedule 13D or 13G filings on record since 2026-03-26. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 16,045,802 | SCHEDULE 13G, 2026-06-02 | 2026-05-26 |
| TCG Crossover GP III, LLC | 9.9% | 15,798,999 | SCHEDULE 13G, 2026-06-03 | 2026-05-27 |
| BlackRock, Inc. | 7.8% | 11,937,882 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| RA Capital Management, L.P. | 5.8% | 8,889,000 | SCHEDULE 13G, 2026-06-03 | 2026-05-27 |
| ADAR1 Capital Management, LLC | 5.8% | 8,889,000 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind Editas Medicine, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Editas Medicine, Inc. and the records around it.
Editas Medicine, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- TCG Crossover GP III, LLC also filed stake reports on 3 other companies: Research Alliance Corporation III (Aug 2026), Entera Bio Ltd. (Aug 2026), InflaRx N.V. (May 2026)
- ADAR1 Capital Management, LLC also filed stake reports on 29 other companies: InMed Pharmaceuticals, Inc. (Oct 2026), Tenax Therapeutics, Inc. (Sep 2026), Adagio Medical Holdings, Inc. (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
Watch Editas Medicine, Inc.
Get an email when Editas Medicine, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Editas Medicine, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Editas Medicine, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Editas Medicine, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Commodore Capital LP | 0 | 16,045,802 | 0 | 16,045,802 | SCHEDULE 13G, 2026-06-02 |
| Commodore Capital Master LP | 0 | 16,045,802 | 0 | 16,045,802 | SCHEDULE 13G, 2026-06-02 |
| Robert Egen Atkinson | 0 | 16,045,802 | 0 | 16,045,802 | SCHEDULE 13G, 2026-06-02 |
| Michael Kramarz | 0 | 16,045,802 | 0 | 16,045,802 | SCHEDULE 13G, 2026-06-02 |
| TCG Crossover GP III, LLC | 0 | 15,798,999 | 0 | 15,798,999 | SCHEDULE 13G, 2026-06-03 |
| TCG Crossover Fund III, L.P. | 0 | 15,798,999 | 0 | 15,798,999 | SCHEDULE 13G, 2026-06-03 |
| Chen Yu | 0 | 15,798,999 | 0 | 15,798,999 | SCHEDULE 13G, 2026-06-03 |
| BlackRock, Inc. | 11,732,765 | 0 | 11,937,882 | 0 | SCHEDULE 13G, 2026-10-27 |
| RA Capital Management, L.P. | 0 | 8,889,000 | 0 | 8,889,000 | SCHEDULE 13G, 2026-06-03 |
| Peter Kolchinsky | 0 | 8,889,000 | 0 | 8,889,000 | SCHEDULE 13G, 2026-06-03 |
| Rajeev Shah | 0 | 8,889,000 | 0 | 8,889,000 | SCHEDULE 13G, 2026-06-03 |
| RA Capital Healthcare Fund, L.P. | 0 | 8,889,000 | 0 | 8,889,000 | SCHEDULE 13G, 2026-06-03 |
| ADAR1 Capital Management, LLC | 0 | 8,889,000 | 0 | 8,889,000 | SCHEDULE 13G, 2026-08-14 |
| Daniel Schneeberger | 0 | 8,889,000 | 0 | 8,889,000 | SCHEDULE 13G, 2026-08-14 |
The latest filing identifies Editas Medicine, Inc. by CUSIP 28106W103 and gives its principal executive office as 11 HURLEY ST., CAMBRIDGE, MA 02141 (SCHEDULE 13G, 2026-10-27).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-06-03
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-06-02 | Commodore Capital LP | 9.9% | SCHEDULE 13G |
| 2026-06-03 | TCG Crossover GP III, LLC | 9.9% | SCHEDULE 13G |
| 2026-06-03 | RA Capital Management, L.P. | 5.8% | SCHEDULE 13G |
| 2026-07-29 | BlackRock, Inc. | 4.97% | SCHEDULE 13G/A |
| 2026-08-14 | ADAR1 Capital Management, LLC | 5.8% | SCHEDULE 13G |
| 2026-10-27 | BlackRock, Inc. | 7.8% | SCHEDULE 13G |
Questions about who owns Editas Medicine, Inc.
Who owns Editas Medicine, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Editas Medicine, Inc.: Commodore Capital LP (9.9%, Schedule 13G, filed 2026-06-02), TCG Crossover GP III, LLC (9.9%, Schedule 13G, filed 2026-06-03), BlackRock, Inc. (7.8%, Schedule 13G, filed 2026-10-27), RA Capital Management, L.P. (5.8%, Schedule 13G, filed 2026-06-03) and ADAR1 Capital Management, LLC (5.8%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Editas Medicine, Inc.?
By the share each holder's latest filing reports, the largest holders of Editas Medicine, Inc. on this page are Commodore Capital LP (9.9%), TCG Crossover GP III, LLC (9.9%) and BlackRock, Inc. (7.8%).
When did Commodore Capital LP buy into Editas Medicine, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Commodore Capital LP on this page is the Schedule 13G, filed 2026-06-02, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Editas Medicine, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 5, 2026 | Leadership change: Patrick Ellinor appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Editas Medicine, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.